Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)

NCT04634357 is registered in ClinicalTrials.gov with Eureka Therapeutics Inc. as lead sponsor.

NCT NCT04634357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04634357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)
Lead sponsor
Eureka Therapeutics Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 19, 2022
Completion date
January 31, 2028
Enrollment
12 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hemnos, hepatoblastoma, hepatocellular carcinoma (hcc), liver cancer, liver neoplasms, metastatic liver cancer